These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15617169)

  • 41. [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases--20 fatal cases].
    Tracqui A; Tournoud C; Flesch F; Kopferschmitt J; Kintz P; Deveaux M; Ghysel MH; Marquet P; Pépin G; Petit G; Jaeger A; Ludes B
    Presse Med; 1998 Mar; 27(12):557-61. PubMed ID: 9767947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
    Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians].
    De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
    Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A27-32. PubMed ID: 10855374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Buprenorphine Provision by Early Career Family Physicians.
    Tong ST; Hochheimer CJ; Peterson LE; Krist AH
    Ann Fam Med; 2018 Sep; 16(5):443-446. PubMed ID: 30201642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination.
    Petry NM; Bickel WK
    Drug Alcohol Depend; 2000 Feb; 58(1-2):27-33. PubMed ID: 10669052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Buprenorphine treatment: a three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan.
    Cozzolino E; Guglielmino L; Vigezzi P; Marzorati P; Silenzio R; De Chiara M; Corrado F; Cocchi L
    Am J Addict; 2006; 15(3):246-51. PubMed ID: 16923672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
    Jovanović T; Lazarević D; Nikolić G
    Vojnosanit Pregl; 2012 Apr; 69(4):326-32. PubMed ID: 22624424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.
    Jacobs P; Ang A; Hillhouse MP; Saxon AJ; Nielsen S; Wakim PG; Mai BE; Mooney LJ; S Potter J; Blaine JD
    Am J Addict; 2015 Oct; 24(7):667-75. PubMed ID: 26400835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buprenorphine treatment: factors and first-hand experiences for providers to consider.
    Meier BR; Patkar AA
    J Addict Dis; 2007; 26(1):3-14. PubMed ID: 17439863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

  • 58. [Opiate substitution: the users' point of view].
    Chappard P
    Ann Pharm Fr; 2009 Sep; 67(5):365-8. PubMed ID: 19695373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.